TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03816748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula, HFNC
Description: The HFNC used in this study can supply more than 40-60 L/min of oxygen flow, which is many times higher than the traditional nasal cannula. In addition, HFNC provides heating and moisturizing functions, so the patients 'nasal and oropharyngeal cavities do not dry out. This way, the patients can wear HFNC continuously for many days. Furthermore, when the patients close their mouths, HFNC can create a PEEP of 6-8 cmH2O, which helps with lung expansion after chest surgeries and lowers the risk of pneumonia related to lung collapses.
Study: NCT03028974

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone®
Description: Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone®
Description: Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone®
Description: Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist®
Description: FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist®
Description: FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist®
Description: FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist®
Description: FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray
Study: NCT00796770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Biological/Vaccine: Experimental: Dendritic Cell Vaccine Patients will receive 4 doses of the vaccine at weeks 0, 4, 8 and 12. The vaccine will be injected subcutaneously, in 3 separate injection sites in the upper and lower extremities.~At week 24, patients will have HAART treatment interrupted. The HAART treatment will be resumed at week 48 or earlier at any time point if one of the following occur:~1. two consecutive measurements of CD4+ T cell count below 350x10e6 cells/L and/or 25% of total lymphocytes within at least a 2 weeks~2. an opportunistic infection~3. a CDC class C-defining event (defined in appendix 2)~4. a serious non-AIDS defining event.~Patients will have follow-up visits on weeks: 22, 24, 25, 26, 27, 28, 32, 36, 40, 44, and 48.
Study: NCT02293044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crest® Sensi-Stop™ Strips
Study: NCT02351531

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extensively Hydrolyzed formula
Study: NCT02959632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Therapy
Description: Animal Assisted Therapy is the program where a pet, usually dog will visit and interact with the patients.
Study: NCT03912558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Butterfly device implantation
Description: The Butterfly device will be positioned and deployed with cystoscopy guidance
Study: NCT03950570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: In patients with relapsed. metastatic breast cancer, ORIN1001 will be administered in combination with Abraxane administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIN1001
Description: ORIN1001 will be administered as a table as a monotherapy in the dose escalation phase in patients with advanced solid tumors or in combination with Abraxane in patients with relapse, refractory breast cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIN1001
Description: ORIN1001 will be administered as a table as a monotherapy in the dose escalation phase in patients with advanced solid tumors or in combination with Abraxane in patients with relapse, refractory breast cancer
Study: NCT03178617

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Attend standard of care LIP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend HIP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03085485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivacaftor 150 MG
Description: Ivacaftor is a CFTR potentiator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pills
Study: NCT03152253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text My Quit (TMQ)
Description: Text messages designed to aid smoking cessation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Peer Support
Description: A group chat room for peer support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: A group chat room for peer support

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Motivational Messages
Description: Generic motivational messages not related to smoking cessation
Study: NCT02748915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrophysiological and psychoacoustic tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrophysiological and psychoacoustic tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrophysiological and psychoacoustic tests
Study: NCT00802074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400mg BID, 700 mg BID or 1400 mg QD
Study: NCT04108468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate
Study: NCT00802074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg BID or QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg BID or QD
Study: NCT02449486

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study: NCT03788993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue-depleted evening light condition
Description: A 20-bedded ward with tunable light emitting diode (LED) lamps. At 18:00h the lighting undergoes a 30-minute transition during which the green and blue LEDs are dimmed to produce blue-depleted amber colored lighting. At 06:50h a new 10-minute transition changes the light color to ordinary indoor lighting. From 07:00h to 18:00h, there is ordinary indoor lighting (3000K colour temperature). The light intensity is dimmed to 20% of the maximum from 23:00h to 6:50h.~Blue-blocking window filters are deployed also in the evening. All TV sets have permanent blue-blocking filters and individuals are provided with blue-blocking screens that can be attached to the front of personal electronic devices. If the patients leave the blue-depleted unit after 18:30 they are offered blue-blocking glasses to wear. The light spectrum in the ward was assessed prior to commencing the RCT and is well-matched to what has been shown in laboratory settings to minimally suppress melatonin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal light condition
Description: The other half of the unit (20 patient rooms and their corresponding bathrooms and common areas) have ordinary indoor light installed (Glamox, Norway). This has a 3000K color temperature. The light is dimmed to 20% of max in the night, similar to the blue-depleted condition.~The light in the normal light condition and the blue-depleted light condition have similar levels of photopic lux throughout the 24h cycle, but different levels of melanopic lux between 1830h and 0700h.
Study: NCT03364465

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: change of ventilatory settings
Description: change of tidal volume during one-lung ventilation
Study: NCT02322112

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose Supplementation
Description: Fifty overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of MCC (Females: 25 g; Males: 35 g) daily for six consecutive weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acacia Gum Supplementation
Description: Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of AG (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
Study: NCT01007721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast placebo tablet
Description: 1 over-encapsulated montelukast placebo tablet (qd in the morning)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast placebo tablet
Description: 1 over-encapsulated montelukast placebo tablet (qd in the morning)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast 10 mg tablet
Description: 1 over-encapsulated montelukast 10 mg tablet (qd in the morning)
Study: NCT02322112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4 Supplementation
Description: Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of RS4 (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
Study: NCT02426905

Intervention type: DRUG
Group type: OTHER
Intervention: trientine dihydrochloride
Description: A retrospective review of patients' medical records
Study: NCT01453270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICOM
Description: Assessment of fluid responsiveness will be done using the non-invasive cardiac output monitor (NICOM) and passive leg-raising (PLR) maneuver to target mean arterial pressure of between 65mmHg and 90mmHg; and change in stroke volume index (SVI) less than 10%, prior to administration of fluid boluses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care is given at the clinician's discretion in accordance with current best practice. Standard treatment may involve treatment with intravenous fluids, and medications to support the blood pressure and heart.
Study: NCT00910533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: ceftriaxone 2 g od i.v. for 14 days
Study: NCT00183404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine tablets, dosed once or twice per day, dosage 2.5 to 20 mg per day
Study: NCT02443714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle-free jet injection with insulin lispro
Description: Subjects injected by jet injectors which deliver insulin lispro

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional pen injection with insulin lispro
Description: Subjects injected by conventional insulin pens which deliver insulin lispro
Study: NCT03738436

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy traditional neuromuscular training, NMT
Description: The NMT program includes re-position exercise using Swiss ball roll squat, strengthening and stretching exercises in various positions or combined using Swiss ball, Thera-Band or suspension system (Redcord), balance exercise on wobble board, proper landing strategy practices, and etc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy modified visual feedback, MVF
Description: traditional neuromuscular training (as in NMT group), but with modified visual feedback by eyes closed, reduced lighting or wearing strobe goggles
Study: NCT02653781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Realistic simulation
Description: The students enrolled and selected according to the inclusion criteria will be randomized into two groups. The experimental group will experience the combined teaching methodology: dialogue-exhibition and realistic simulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control group
Description: The control group will have contents exposed solely from the dialogue-exhibition.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: control group
Description: The control group will have contents exposed solely from the dialogue-exhibition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation workshop
Description: Check the performance of students in face of simulated situations on medication administration by intramuscular and intravenous routes experienced in the Skills and Care Simulation Laboratory.
Study: NCT00802074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg BID or QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg BID or QD
Study: NCT02119351

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ViaValve™ Safety IV Catheter
Description: Safety peripheral IV catheter with a blood control feature

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProtectIV® Plus Safety IV Catheter
Description: Safety peripheral IV catheter with no blood control feature
Study: NCT00843167

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: broccoli sprout extract
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT03671837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: 15 L/min O2

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air
Description: 15 L/min air
Study: NCT01662310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) up to 12 mg once daily for 8 weeks in Run-in or Stabilization phase, and 3-12 mg fixed dose oral tablet will be administered in DB phase. Participants who will enter open-label extension phase will receive paliperidone as 3-12 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) up to 12 mg once daily for 8 weeks in Run-in or Stabilization phase, and 3-12 mg fixed dose oral tablet will be administered in DB phase. Participants who will enter open-label extension phase will receive paliperidone as 3-12 mg per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants who transitioned from run-in or stabilization phase will receive matching placebo to paliperidone ER once daily during DB phase of the study.
Study: NCT03577210

Intervention type: PROCEDURE
Group type: OTHER
Intervention: augmentation genioplasty
Description: augmentation genioplasty with patient-specific PEEK implant
Study: NCT04233866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: Given IV
Study: NCT02653781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Test realistic simulation
Description: Occurs after the end of the three-month intervention. At that time, students from the control and intervention groups will be asked to take a knowledge retention test in cognitive assessment format and OSCE format (objective structured clinical examination).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Test realistic simulation
Description: Occurs after the end of the three-month intervention. At that time, students from the control and intervention groups will be asked to take a knowledge retention test in cognitive assessment format and OSCE format (objective structured clinical examination).
Study: NCT04233866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01342770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04484428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-285
Description: 88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menthol
Description: 88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
Study: NCT04259268

Intervention type: OTHER
Intervention: Quality of preoperative information register
Description: Register of principal (grade ASA classification) and secondary variables (allergies, antiplatelet or blood thinners prescriptions, cardiovascular diseases, present medication)

Intervention type: OTHER
Intervention: Quality of preoperative information register
Description: Register of principal (grade ASA classification) and secondary variables (allergies, antiplatelet or blood thinners prescriptions, cardiovascular diseases, present medication)

Intervention type: OTHER
Intervention: Quality of preoperative information register
Description: Register of principal (grade ASA classification) and secondary variables (allergies, antiplatelet or blood thinners prescriptions, cardiovascular diseases, present medication)

Intervention type: OTHER
Intervention: Suitability of information contained in the informed consent
Description: Register of information regarding specific individual risks and personal data (patient and doctor identification and signature)

Intervention type: OTHER
Intervention: Suitability of information contained in the informed consent
Description: Register of information regarding specific individual risks and personal data (patient and doctor identification and signature)
Study: NCT03249519

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 50.4 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: 35-40 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: weekly 40 mg/m\^2 (6cycles)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: 10 times
Study: NCT01817413

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mineral trioxide aggregate
Description: An apical barrier of mineral trioxide aggregate (MTA cement) will be placed in the tooth root at the open apex in order to achieve root end closure via an apexification technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revascularisation
Description: Pulp revascularisation will be induced by instrumentation through the open apex so that a blood clot forms within the root canal in order to achieve root end closure via apexogenesis
Study: NCT01007721

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluticasone propionate placebo nasal spray
Description: fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate nasal spray placebo
Description: fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
Study: NCT01542489

Intervention type: DRUG
Intervention: insulin detemir
Description: Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any

Intervention type: DRUG
Intervention: insulin detemir
Description: Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any

Intervention type: DRUG
Intervention: insulin aspart
Description: Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any

Intervention type: DRUG
Intervention: human soluble insulin
Description: Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any